Novel systemic therapies for the treatment of psoriasis. (2nd January 2016)

• Record Type: Journal Article
• Authors: Tan, Ki-Wei; Griffiths, Christopher EM
• Is Part Of: Expert opinion on pharmacotherapy. Volume 17:Number 1(2016)
• Page Start: 79
• Page End: 92
• Publication Date: 2016-01-02
• Subjects: biologic -- IL-17 -- IL-23 -- JAK inhibitor -- novel -- phosphodiesterase-4 inhibitor -- psoriasis -- small molecules -- systemic; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1517/14656566.2016.1109636
• Languages: English
• ISSNs: 1465-6566

Abstract

Abstract : Introduction : The immunopathogenesis of psoriasis has led to the discovery and development of several promising treatment options for psoriasis, including those that target the IL-17 and IL-23 pathways as well as small molecules that act on intracellular signaling pathways including the Janus kinase inhibitor and phosphodiesterase-4 inhibitor. Studies have demonstrated efficacy although long-term risks are not fully known. This review looks at novel systemic therapies for psoriasis that have emerged recently. Areas covered : Systemic treatments for psoriasis that are in the late phase of development were reviewed, with the main focus on the efficacy and adverse effects of individual treatments. Expert opinion : The future of psoriasis treatment is likely to be based on clinical, genetic and immune biomarkers that will individualize treatment and may potentially optimize disease outcome.